Bioblast Pharma Ltd. Report issue

For profit Phase 1 Phase 3
Founded: Tel Aviv Israel (2012)
Status: Acquired by Seelos Therapeutics (2019)

Organization Overview

First Clinical Trial
2014
NCT02015481
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bioblast Pharma Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

trehalose (5 trials)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Machado-Joseph Disease (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Oculopharyngeal (Phase 3)

Spinocerebellar Ataxias (Phase 2)

Spinocerebellar Degenerations (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2